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and 0.0099 (SE  0.0085; 90% CI: 0.00002, 0.028) under one of the Beta-based esti-
mators, while other Beta-based estimators produced similar results. Our simulation 
results revealed substantial advantage of the Beta-based estimators over OLS when 
the true incremental effect is large, but this advantage dissipates as the incremental
effect gets smaller. CONCLUSIONS: One and two-part Beta regression models can
provide substantial beneﬁ ts, both in terms of bias and efﬁ ciency, over traditional OLS
regression in modeling quality of life data such as EQ5D only when the true incre-
mental effects are large but not when they are small. Our case study conﬁ rms these 
conclusions. Further exploration is required to provide deﬁ nite ranges of incremental
effects where alternative methods are to be preferred.
CONCEPTUAL PAPERS & RESEARCH ON METHODS – 
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SURVEY (MEPS): A FACETS MODEL APPROACH
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OBJECTIVES: To evaluate the measurement property of the EQ-5D and to test the 
role of time in affecting the unidimensionality in EQ-5D. METHODS: We extracted 
a sample from the two-year panel (2002–2003) in Medical Expenditure Panel 
Survey (MEPS). Respondents were included if they completed the EQ-5D, were q18 
years of age and were diagnosed with any of the top ten most prevalent chronic condi-
tions using ICD-9-CM (n  1428). Data sets using point-in-time−were constructed 
to analyze the EQ-5D 1) cross-sectional two repeated measures for each respondent. 
For−measures and, 2) longitudinal cross-sectional study, we used Rasch rating scale 
model. For longitudinal analysis, we applied FACETS model by parameterizing 
time with the hypothesis that time plays a signiﬁ cant role in characterizing the unidi-
mensionality of the EQ-5D. Unidimensionality was evaluated using the goodness-
of-ﬁ t of the EQ-5D items to the measurement models. Time severity effect was
examined via item x time interactions to evaluate the measurement invariance pro-
perty of the EQ-5D. RESULTS: Results from both point-in-time measures revealed 
that the mental health item “anxiety/depression” consistently showed misﬁ t in all 
chronic conditions (INFIT/OUTFIT mean square 1.3). Results from longitudinal
analysis demonstrated that including time rendered improved model ﬁ t as unidimen-
sionality of the EQ-5D was achieved in eight out of ten chronic conditions. There was 
signiﬁ cant time severity effects (p  0.05) indicating that the EQ-5D items were 
endorsed differently over time. CONCLUSIONS: Most analysis of health measures 
suggest unidimensionality fails because mental health and physical health items tend
to form different scales. Our ﬁ ndings suggest that time mediates unidimensionality 
and that physical health and mental health are linked through time. As time is essential 
to all chronic disease prognoses, controlling for time in a longitudinal study of health 
measurement is important for proper assessment on the measurement properties of 
health instruments.
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CULTURAL ADAPTATION AND VALIDATION OF A HEATH RELATED
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OBJECTIVES: The aim of this study was to determine the reliability and validity of 
the Functional Outcomes of Sleep Questionnaire (FOSQ) for the Turkish population.
METHODS: A total of 200 university students participated. A total of 52% of them 
were men, 48% of them were women. A total of 43% of them lived in the dormitory
and 57% of them lived at the apartments. Data were collected with a sociodemo-
graphic form, FOSQ, and SF-36. Cronbach’s Alfa was used to assess reliability and
factor analysis to assess dimensionality. The SF-36 was used for concurrent validity.
RESULTS: The internal consistency coefﬁ cient (Cronbach’s alpha) of FOSQ was 0.90. 
Factor analysis of the scale revealed that it was composed of three factors with Eigen-
values 2.0, accounting for 57.6% of the total variance. All items of the Turkish FOSQ
had a factor load ranging from 0.413 to 0.731. There was a strong relationship
between Functional Outcomes of Sleep Questionnaire, and SF-36. CONCLUSIONS:
The culturally adapted Functional Outcomes of Sleep Questionnaire had good validity 
and reliability, making it a potentially useful outcome measure in the evaluation of 
insomnia patients in Turkey.
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OBJECTIVES: To evaluate the item measurement property of the SF-12v2™ and the 
merits of the physical and mental health component scales (PCS and MCS) using Rasch 
model. METHODS: We extracted a sample from the 2005 Medical Expenditure Panel 
Survey (MEPS). We included respondents who had completed the SF-12v2™, were 
q18 years of age and were diagnosed with any of the top ten most prevalent chronic
conditions using the primary ICD-9-CM (n  5151). Rasch analyses were applied
repeatedly in subgroups on all SF-12v2™ items as a 12-item scale as well as on PCS 
and MCS items separately as two 6-item scales. Items were evaluated using the Rasch 
model ﬁ t statistics to examine 1) whether or not the 12 items measure a unidimen-
sional construct and 2) whether or not PCS items measure a physical health construct 
and MCS items measure a mental health construct. RESULTS: In the 12-item scale, 
the two mental health (MH) items “Have you felt calm and peaceful” and “Have you
felt downhearted and depressed” consistently demonstrating misﬁ t in all subgroups
(inﬁ t/outﬁ t mean square 1.3). By subdividing the PCS and MCS items into two sepa-
rate 6-item scales, all six MCS items had good model ﬁ t including the two MH items.
On the other hand, two PCS items concerning respondents’ general health and bodily
pain showed misﬁ t to the Rasch model. CONCLUSIONS: The SF-12v2™ items do
not form a unidimensional scale as the two MH items did not ﬁ t with other ten items.
However, there are tradeoffs treating PCS and MCS as two distinctive scales as PCS 
items had a reduced ﬁ t. A generic SF-10 for adult population may be a unidimensional
component of the SF-12v2™ and could serve as a brief health survey instrument that 
improves upon the SF-12v2™.
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OBJECTIVES: This study explored children’s perceptions of inﬂ uenza and their ability
to make trade-offs among ﬂ u vaccine attributes. METHODS: A qualitative study was 
performed to inform the development of a conceptual model on children’s perceptions 
of inﬂ uenza vaccination. Interviews were conducted by a trained interviewer using an
interview guide. A thematic analysis was conducted to understand perceptions of 
inﬂ uenza and vaccination including inﬂ uenza vaccine attributes such as efﬁ cacy, side
effects, and mode of administration. Study subjects were children aged 6 through 12 
years from the Washington, DC area. RESULTS: A total of 28 children (two males 
and two females per year of age) participated. Parents reported that 75% of the chil-
dren had previously been vaccinated against the inﬂ uenza virus. Knowledge of inﬂ u-
enza varied among children; some were unable to describe inﬂ uenza-illness, while 
others described it as a virus and were able to list speciﬁ c symptoms. Once inﬂ uenza 
was described by the interviewer, all children demonstrated a basic understanding of 
the illness. Efﬁ cacy, risk of side effects and mode of administration were found to 
impact children’s decision to be vaccinated. Children as young as 8-years old were 
able to differentiate low, medium and high risk of side effects and showed the ability
to make rational and consistent tradeoffs between vaccines with differing levels of 
efﬁ cacy, chance of side effects and/or mode of administration. Under certain vaccine 
scenarios, each child was willing to be vaccinated. CONCLUSIONS: Children may
be able to make decisions pertaining to inﬂ uenza vaccination. Young children appear 
to understand the concept of risk and are able to make trade-offs among inﬂ uenza 
vaccine attributes.
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OBJECTIVES: To determine the inﬂ uence of the FDA Draft PRO Guidance on obtain-
ing PRO label claims, for drug products in the US, since its release in February 2006. 
METHODS: Package inserts (indication, clinical trials sections) and medical review
sections from publicly available summary basis of approvals (SBA) for FDA approved
drug products named by the MAPI PROLabels database as having a US-based PRO 
label claim between February 2006 and August 2008 were reviewed. RESULTS: Of 
33 products reviewed, 44 PRO claims were granted. Signs and symptoms (SS) repre-
sented the majority (n  32; 73.7%) of the claims. Within this category, the greatest
number of claims were pain-related (primarily based on a VAS or NRS rating scale)
and more than half of all SS claims were based on a patient diary. After SBA review
for the 24 drug products identiﬁ ed with an available medical review, 13 products were
found to have collected additional PRO within the context of the registration trial 
(reported in the medical review) that did not result in a PRO claim; of these, 6 had
PROs reported to have statistically signiﬁ cant results and 2 of these (Voltaren and 
Fentora) reported clinically meaningful results. Both products were reviewed by the 
same FDA Division of Anesthesia, Analgesia, & Rheumatology (DAAR) and are 
indicated for pain. Of the 33 products reviewed, the Pulmonary and Allergy Products
reviewing division reviewed the most products (nine) and allowed the most PRO
claims (eleven) in the label. Of the 33 products reviewed, SEALD was involved in 4 
product SBA reviews. CONCLUSIONS: Evidence suggests that since the release of the
Draft PRO Guidance, many PRO claims continue to be approved by FDA reviewing 
divisions; however, the reviewing divisions are not always adhering to the current
standards when assessing PRO data for a claim.
